Skip to main content

Tethys Bioscience Buys Lipomics

NEW YORK (GenomeWeb News) – Diagnostics developer Tethys Bioscience said today that it has bought Lipomics Technologies, a metabolite-profiling firm, for an undisclosed sum.
 
Tethys, which earlier this year began selling a test for diabetes risk, said the acquisition will help it to develop new tests to predict the likelihood of developing chronic diseases. Currently, Emeryville, Calif.-based Tethys is developing a test to predict the likelihood that a person will experience osteoporotic bone fracture or a major cardiac event.
 
All of Lipomics’ 30 employees will become part of Tethys, and Lipomics’ Co-founder and Chief Scientific Officer Steven Watkins will become Tethys’ chief technology officer.
 
Lipomics’ facility will continue handling quantitative lipid metabolite profiling as Tethys West Sacramento.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.